Bio-Techne Corporation

What they do

Bio-Techne operates in two segments: Protein Sciences and Diagnostics and Spatial Biology. Protein Sciences sells purified proteins (cytokines, growth factors), antibodies, immunoassays, and protein analysis tools. Diagnostics and Spatial Biology provides FDA-regulated controls, calibrators, molecular diagnostic assays, and spatial biology instrumentation. Products are manufactured in the U.S., U.K., Canada, Switzerland, and China.

Revenue drivers

• Protein Sciences — Leading supplier of specialized proteins, antibodies, immunoassays, and reagents to biopharma and academic research. Q4 FY2026 net sales were $231.2M, up 2% from $226.5M a year earlier.
• Diagnostics and Spatial Biology — Sells regulated diagnostic controls/calibrators, molecular diagnostic assays, and spatial biology instruments. Organic growth in FY2024 was driven by strong commercial execution in this segment.
• Acquisitions and investments — Acquisitions (e.g., Lunaphore, Spear Bio) and a 19.9% stake in Wilson Wolf (to be fully acquired by end of 2027) contribute to portfolio expansion and growth.

Recent performance

For Q4 FY2026 (quarter ended June 30, 2026), revenue increased 1% to $321.2M, with organic growth of 3%. Full-year FY2026 revenue was flat at $1.2B. GAAP EPS for Q4 was $0.35, up from $(0.11) a year ago; adjusted EPS was $0.52, down from $0.53. For the full year, GAAP EPS rose to $1.16 from $0.46, and adjusted EPS to $1.93 from $1.92. Adjusted operating margin for Q4 improved to 32.2% from 32.0%.

Strategy

Management cites four strategic pillars: grow and leverage the core, capitalize on high-potential markets, market expansion through innovation and acquisition, and deliver best-in-class customer experience. The company uses disciplined M&A to fill portfolio gaps and diversify, with recent examples including Lunaphore and Spear Bio. It also plans to fully acquire Wilson Wolf by 2027 or earlier upon milestone achievement. The pending acquisition by Merck KGaA for $73 per share (enterprise value ~$11.3B) is expected to close and will define the near-term strategy.

Risks

• Global economic sensitivity — Slower economic growth, inflation, or changes in government research funding could reduce demand for the company's products.
• Acquisition integration — Integration of acquisitions like Lunaphore and the planned Wilson Wolf purchase may not achieve expected synergies or growth targets.
• Foreign exchange exposure — Sales in euro, pound sterling, yuan, and Swiss franc are subject to currency fluctuation, which can impact reported revenue.
• Pending Merck transaction risk — The acquisition by Merck KGaA is subject to regulatory approvals and other conditions; failure to complete could adversely affect the business.

Outlook

Management expects the Merck KGaA acquisition to create opportunities for customers and employees and is working toward completion. For FY2026, full-year revenue was flat, but organic growth returned to positive in Q4. The company does not hold investor conference calls after the announced transaction.